CIP2A expression predicts recurrences of tamoxifen-treated breast cancer
CIP2A is emerging as an oncoprotein overexpressed commonly across many tumours and generally correlated with higher tumour grade and therapeutic resistance. CIP2A drives an oncogenic potential through inhibiting protein phosphatase 2A, stabilizing MYC, and promoting epithelial-to-mesenchymal transit...
Saved in:
| Main Authors: | Shawn Baldacchino, Laura M Wastall, Christian Saliba, Thomas A Hughes, Christian Scerri, Angelene Berwick, Valerie Speirs, Andrew M Hanby, Godfrey Grech |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-10-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317722064 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CYP2D6 genotype and outcome in tamoxifen treated early breast cancer
by: Linda Thorén, et al.
Published: (2025-07-01) -
CIP2A promotes inflammation and exacerbates osteoarthritis by targeting CEMIP
by: Jingyue Su, et al.
Published: (2025-06-01) -
CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice.
by: Sami Ventelä, et al.
Published: (2012-01-01) -
New AIM/CIPS global observations of gravity waves near 50–55 km
by: C. E. Randall, et al.
Published: (2017-07-01) -
Clinical and pharmacogenomic predictors of survival in tamoxifen treated breast cancer female patients: a real-world study
by: Abdullah R. Al-Matrafi, et al.
Published: (2025-06-01)